Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.

Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2012 Jun;22(5):801-6. doi: 10.1097/IGC.0b013e3182540145.

PMID:
22617480
2.

Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Fujiwara S, Kawai M, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2012 Mar;22(3):394-9. doi: 10.1097/IGC.0b013e31823eed2c.

PMID:
22391762
3.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
4.

Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:305-10. doi: 10.1016/j.ejogrb.2014.07.046. Epub 2014 Aug 20.

PMID:
25203309
5.

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J.

Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24.

6.
7.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
8.

Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Petrillo M, De Iaco P, Cianci S, Perrone M, Costantini B, Ronsini C, Scambia G, Fagotti A.

Ann Surg Oncol. 2016 May;23(5):1660-5. doi: 10.1245/s10434-015-5050-x. Epub 2015 Dec 29.

PMID:
26714958
9.

Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer.

Lee M, Kim SW, Lee SH, Paek J, Yim GW, Kim GE, Kim S, Kim JH, Kim YT, Nam EJ.

Int J Gynecol Cancer. 2011 Aug;21(6):1032-9. doi: 10.1097/IGC.0b013e31821e0353.

PMID:
21738040
10.

[Analysis of prognostic factors of epithelial ovarian carcinoma].

Shao SL, Liu XS.

Zhonghua Fu Chan Ke Za Zhi. 2010 Feb;45(2):132-6. Chinese.

PMID:
20420785
11.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

13.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.

Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z. Epub 2012 Oct 2.

PMID:
23054114
14.

Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.

Higashi M, Kajiyama H, Shibata K, Mizuno M, Mizuno K, Hosono S, Kawai M, Nakanishi T, Nagasaka T, Kikkawa F.

Gynecol Oncol. 2011 Dec;123(3):474-8. doi: 10.1016/j.ygyno.2011.08.036. Epub 2011 Sep 28.

PMID:
21955484
15.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.

Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2011 Aug;21(6):1040-7. doi: 10.1097/IGC.0b013e31821e052e.

PMID:
21738039
16.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
17.

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS.

Br J Cancer. 2011 Sep 27;105(7):890-6. doi: 10.1038/bjc.2011.328. Epub 2011 Aug 30.

18.

Impact of prognostic factors on survival rates in patients with ovarian carcinoma.

Arikan SK, Kasap B, Yetimalar H, Yildiz A, Sakarya DK, Tatar S.

Asian Pac J Cancer Prev. 2014;15(15):6087-94.

19.

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T.

Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906.

PMID:
21792012
20.

Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.

Shaboodien R, Diamantis N, Blagden S, Gabra H, Agarwal R.

Int J Gynecol Cancer. 2013 Mar;23(3):481-7. doi: 10.1097/IGC.0b013e31828702f6.

PMID:
23392404

Supplemental Content

Support Center